Price Chart

Executive Summary

Rhythm Pharmaceuticals announced additional positive 52-week data from its Phase 3 TRANSCEND trial showing a -18.8% placebo-adjusted BMI reduction for setmelanotide in patients with acquired hypothalamic obesity (HO), supporting its supplemental New Drug Application (sNDA) currently under FDA review with a PDUFA decision date of March 20, 2026. The data include Japanese and supplemental cohorts, strengthening the clinical package ahead of regulatory decisions in the U.S., EU, and planned submission in Japan.

Key Facts

• Setmelanotide showed a -18.8% placebo-adjusted difference in BMI reduction at 52 weeks in 142 patients with acquired hypothalamic obesity.
• Primary endpoint: -16.4% mean BMI reduction from baseline in setmelanotide group vs. +2.4% in placebo (p<0.0001).
• In patients aged 12+, setmelanotide reduced weekly average most hunger score by 2.5 points vs. 1.3 in placebo (p=0.0015).
• FDA PDUFA goal date for sNDA is March 20, 2026; final data package to be submitted March 2, 2026.
• EMA review ongoing with CHMP opinion expected in Q2 2026 and potential EU approval in H2 2026.
• Plans to submit full data to Japan’s PMDA for marketing authorization.

Financial Impact

Potential expansion of IMCIVREE's addressable market by up to 38,000 patients across the U.S., EU, and Japan if approved for acquired HO.

Risk Factors

• FDA may not approve the sNDA despite positive data.
• Commercial uptake in acquired HO may be limited by diagnosis challenges and small patient population.
• Safety concerns such as depression, hypersensitivity, and skin hyperpigmentation remain.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status